Integra Lifesciences Holdings Corp (IART) 56.89 $IART
12.9% Return Seen to Date on SmarTrend Integra LifeSciences Call (IART)
Comtex SmarTrend(R) - Wed Feb 11, 11:19AM CST
SmarTrend identified an Uptrend for Integra LifeSciences (NASDAQ:IART) on December 12th, 2014 at $50.30. In approximately 2 months, Integra LifeSciences has returned 12.87% as of today's recent price of $56.77.
IART: 56.89 (+0.62)
Integra LifeSciences to Participate in the RBC Capital Markets' Global Healthcare Conference
GlobeNewswire - Mon Feb 09, 7:06AM CST
Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced that it will present at the following conference in February:
IART: 56.89 (+0.62)
Integra LifeSciences Has Returned 14.0% Since SmarTrend Recommendation (IART)
Comtex SmarTrend(R) - Wed Feb 04, 9:59AM CST
SmarTrend identified an Uptrend for Integra LifeSciences (NASDAQ:IART) on December 12th, 2014 at $50.30. In approximately 2 months, Integra LifeSciences has returned 14.03% as of today's recent price of $57.35.
IART: 56.89 (+0.62)
Integra LifeSciences Announces Submission of a Premarket Approval Supplement Application for the Treatment of Diabetic Foot Ulcers
GlobeNewswire - Tue Feb 03, 5:30PM CST
Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced it has completed the submission of a Premarket Approval (PMA) Supplement application to the United States Food and Drug Administration (the "FDA"
for a new Indication of Use of its Integra (R) Dermal Regeneration Template for the treatment of diabetic foot ulcers. Integra Dermal Regeneration Template is an advanced bilayer skin replacement system designed to provide immediate wound closure and permanent regeneration of the dermis.
IART: 56.89 (+0.62)
Uptrend Call Working As Integra LifeSciences Stock Rises 13.3% (IART)
Comtex SmarTrend(R) - Tue Jan 27, 9:16AM CST
SmarTrend identified an Uptrend for Integra LifeSciences (NASDAQ:IART) on December 12th, 2014 at $50.30. In approximately 2 months, Integra LifeSciences has returned 13.31% as of today's recent price of $56.99.
IART: 56.89 (+0.62)
Integra LifeSciences Launches Integra(R) Reinforcement Matrix
GlobeNewswire - Wed Jan 21, 7:38AM CST
Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced the full market release of Integra(R) Reinforcement Matrix, a biological implant composed of porcine dermis that may be used for any type of tendon injury that requires surgical reconstruction. Tendon injuries are some of the most common musculoskeletal disorders, ranging from a mild ankle sprain to an Achilles tendon rupture or flexor tendon injury of the hand.
IART: 56.89 (+0.62)
Integra LifeSciences Announces Resolution of Warning Letter Related to Its Manufacturing Facility in Anasco, Puerto Rico
GlobeNewswire - Tue Jan 20, 7:00AM CST
Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced the United States Food and Drug Administration (the "FDA" has informed the Company that it had addressed the violations in the warning letter relating to its manufacturing facility in Anasco, Puerto Rico (the "Anasco" facility).
IART: 56.89 (+0.62)
Integra reports February 24
Seeking Alpha - at Seeking Alpha - Wed Jan 14, 3:18PM CST
IART: 56.89 (+0.62)
Integra LifeSciences to Host Its Fourth Quarter 2014 Earnings Results Conference Call on February 24, 2015
GlobeNewswire - Wed Jan 14, 3:05PM CST
Integra LifeSciences Holdings Corporation (Nasdaq:IART) will release its fourth quarter 2014 financial results and issue 2015 financial guidance on Tuesday, February 24, 2015. The company has scheduled a conference call for 8:30 AM ET the same day to discuss the results.
IART: 56.89 (+0.62)
Integra LifeSciences Acquires Metasurg's Foot and Ankle Product Portfolio
GlobeNewswire - Mon Jan 12, 8:16AM CST
Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced that, in December, it closed on the acquisition of the product portfolio from Metasurg.
IART: 56.89 (+0.62)
Insider Trading Alert - STAG, KLAC And IART Traded By Insiders
at The Street - Tue Jan 06, 9:15AM CST
Stocks with insider trader activity include STAG, KLAC and IART
STAG: 25.49 (-0.11), IART: 56.89 (+0.62), KLAC: 63.64 (-0.23)
Integra LifeSciences to Participate in the 33rd Annual J.P. Morgan Healthcare Conference in January
GlobeNewswire - Mon Jan 05, 3:39PM CST
Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced that it will present at the 33 Annual J.P. Morgan Healthcare Conference.
IART: 56.89 (+0.62), JPM: 59.67 (+0.10)
Integra Lifesciences Holdings (IART) Highlighted As Strong And Under The Radar Stock Of The Day
at The Street - Wed Dec 31, 8:47AM CST
Trade-Ideas LLC identified Integra Lifesciences Holdings (IART) as a strong and under the radar candidate
IART: 56.89 (+0.62)
Integra LifeSciences Hits 52-Week High on Portfolio Strength - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 24, 12:00PM CST
Over the last few months, Integra LifeSciences Holdings Corporation (IART) has launched back-to-back products which we believe will enhance the overall product portfolio and also usher in more profitability for the company.
ZMH: 119.33 (+1.18), JNJ: 99.62 (+1.18), IART: 56.89 (+0.62), SYK: 94.51 (+1.14)
How to Invest Money: This Secret Could Save You Thousands
Brian Stoffel, The Motley Fool - Motley Fool - Mon Dec 22, 8:00AM CST
The secret of how to invest money is so simple these kids could get it right. Photo: Flickr user Mike King. Here at The Motley Fool, we try to avoid giving blanket advice on investing, because there are as many paths to financial independence as...
BEBE: 3.90 (+0.01), BIIB: 391.66 (-0.45), PSUN: 2.95 (unch), RECN: 17.46 (-0.15), VALU: 15.10 (+0.09), GRMN: 55.93 (+0.02), QSII: 17.04 (+0.38), AMED: 28.62 (+0.16), UMPQ: 16.82 (+0.17), YHOO: 44.42 (+0.50), RCL: 75.56 (-1.19), IART: 56.89 (+0.62), ATLC: 2.91 (+0.10), AEO: 14.68 (-0.12), ARMH: 49.92 (-0.49), CEB: 79.35 (+0.93), GPS: 41.20 (-0.37)
Integra Lifesciences Up on Launch of Bilayer Skin Product - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Dec 19, 12:40PM CST
This latest single-use skin product of Integra (IART) is at present the only pre-meshed bilayer matrix that has been approved by the FDA to treat patients with third-degree burns and the subsequent scar contracture.
BIIB: 391.66 (-0.45), IART: 56.89 (+0.62), ANIP: 62.69 (-0.43), AFFX: 11.45 (+0.02)
Integra LifeSciences Launches Integra(R) Meshed Dermal Regeneration Template
GlobeNewswire - Wed Dec 17, 7:30AM CST
Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced the expansion of its skin and wound product line with the introduction of IntegraMeshed Dermal Regeneration Template. Integra Meshed Dermal Regeneration Template has received Pre-Market Approval (PMA) from the United States Food and Drug Administration (FDA), and expects to begin a full market release in the United States in January 2015. Integra's newest skin product will be featured at the John A. Boswick Burn and Wound Care Symposium, February 14-18, 2015.
IART: 56.89 (+0.62)
Strong And Under The Radar Today: Integra Lifesciences Holdings (IART)
at The Street - Tue Dec 16, 10:44AM CST
Trade-Ideas LLC identified Integra Lifesciences Holdings (IART) as a strong and under the radar candidate
IART: 56.89 (+0.62)
Italy Tissue Engineered - Skin Substitutes Market Outlook to 2020: Key players covered include Organogenesis, Smith & Nephew and Molnlycke Health Care
M2 - Wed Dec 10, 11:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/gzsh2g/italy_tissue) has announced the addition of the "Italy Tissue Engineered - Skin Substitutes Market Outlook to 2020" report to their offering. Our new report, "Italy Tissue Engineered - Skin Substitutes Market Outlook to 2020", provides key market data on the Italy Tissue Engineered - Skin Substitutes market. The report provides value, in millions of US dollars, volume (in units) and average prices (in US dollars) within market segments - Synthetic Skin Substitutes, Biosynthetic Skin Substitutes and Biologic Skin Substitutes (Allograft (Cellular and Acellular) and Xenograft Acellular). The report also provides company shares and distribution shares data for each of these market categories, and global corporate-level profiles of the key market participants, pipeline products, and news and deals related to the Tissue Engineered - Skin Substitutes market wherever available. The data in the report is derived from dynamic market forecast models. The publisher uses epidemiology and capital equipment-based models to estimate and forecast the market size. The objective is to provide information that represents the most up-to-date data of the industry possible. The epidemiology-based forecasting model makes use of epidemiology data gathered from research publications and primary interviews with physicians to establish the target patient population and treatment flow patterns for individual diseases and therapies. Using prevalence and incidence data and diagnosed and treated population, the epidemiology-based forecasting model arrives at the final numbers. Key Topics Covered: 1 List of Tables 2 Introduction 3 Tissue Engineered - Skin Substitutes Market, Italy 4 Overview of Key Companies in Italy, Tissue Engineered - Skin Substitutes Market 5 Appendix Companies Mentioned: - Organogenesis, Inc. - Molnlycke Health Care AB - Smith & Nephew Plc - BSN medical GmbH - Integra LifeSciences Holdings Corporation - Kinetic Concepts, Inc. - Covidien plc For more information visit http://www.researchandmarkets.com/research/gz...aly_tissue
SNN: 35.82 (-0.28), IART: 56.89 (+0.62)
Asia-Pacific Tissue Engineered - Skin Substitutes Market Outlook to 2020: Key players covered include Japan Tissue Engineering and Smith & Nephew
M2 - Tue Dec 09, 3:47AM CST
Research and Markets (http://www.researchandmarkets.com/research/ctmnfq/asiapacific) has announced the addition of the "Asia-Pacific Tissue Engineered - Skin Substitutes Market Outlook to 2020" report to their offering. Our new report, "Asia-Pacific Tissue Engineered - Skin Substitutes Market Outlook to 2020", provides key market data on the Asia-Pacific Tissue Engineered - Skin Substitutes market. The report provides value, in millions of US dollars, volume (in units) and average prices (in US dollars) within market segments - Synthetic Skin Substitutes, Biosynthetic Skin Substitutes and Biologic Skin Substitutes (Allograft (Cellular and Acellular) and Xenograft Acellular). The report also provides company shares and distribution shares data for each of these market categories, and global corporate-level profiles of the key market participants, pipeline products, and news and deals related to the Tissue Engineered - Skin Substitutes market wherever available. The data in the report is derived from dynamic market forecast models. The publisher uses epidemiology and capital equipment-based models to estimate and forecast the market size. The objective is to provide information that represents the most up-to-date data of the industry possible. Key Topics Covered: 1 List of Tables 2 Introduction 3 Tissue Engineered - Skin Substitutes Market, Asia-Pacific 4 Tissue Engineered - Skin Substitutes Market, Australia 5 Tissue Engineered - Skin Substitutes Market, China 6 Tissue Engineered - Skin Substitutes Market, India 7 Tissue Engineered - Skin Substitutes Market, Japan 8 Tissue Engineered - Skin Substitutes Market, South Korea 9 Overview of Key Companies in Asia-Pacific Tissue Engineered - Skin Substitutes Market 10 Appendix Companies Mentioned: - Japan Tissue Engineering Co., Ltd. - Smith & Nephew Plc - PolyNovo Biomaterials Pty Ltd - Molnlycke Health Care AB - National Tissue Engineering Research Center - L&C Bio - BSN medical GmbH - Covidien plc - Kinetic Concepts, Inc. - CG Bio Inc. - Integra LifeSciences Holdings Corporation - HansBiomed Co., Ltd - Cellumed Co. Ltd For more information visit http://www.researchandmarkets.com/research/ct...siapacific
SNN: 35.82 (-0.28), IART: 56.89 (+0.62)
12.9% Return Seen to Date on SmarTrend Integra LifeSciences Call (IART)
Comtex SmarTrend(R) - Wed Feb 11, 11:19AM CST
SmarTrend identified an Uptrend for Integra LifeSciences (NASDAQ:IART) on December 12th, 2014 at $50.30. In approximately 2 months, Integra LifeSciences has returned 12.87% as of today's recent price of $56.77.
IART: 56.89 (+0.62)
Integra LifeSciences to Participate in the RBC Capital Markets' Global Healthcare Conference
GlobeNewswire - Mon Feb 09, 7:06AM CST
Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced that it will present at the following conference in February:
IART: 56.89 (+0.62)
Integra LifeSciences Has Returned 14.0% Since SmarTrend Recommendation (IART)
Comtex SmarTrend(R) - Wed Feb 04, 9:59AM CST
SmarTrend identified an Uptrend for Integra LifeSciences (NASDAQ:IART) on December 12th, 2014 at $50.30. In approximately 2 months, Integra LifeSciences has returned 14.03% as of today's recent price of $57.35.
IART: 56.89 (+0.62)
Integra LifeSciences Announces Submission of a Premarket Approval Supplement Application for the Treatment of Diabetic Foot Ulcers
GlobeNewswire - Tue Feb 03, 5:30PM CST
Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced it has completed the submission of a Premarket Approval (PMA) Supplement application to the United States Food and Drug Administration (the "FDA"
for a new Indication of Use of its Integra (R) Dermal Regeneration Template for the treatment of diabetic foot ulcers. Integra Dermal Regeneration Template is an advanced bilayer skin replacement system designed to provide immediate wound closure and permanent regeneration of the dermis. IART: 56.89 (+0.62)
Uptrend Call Working As Integra LifeSciences Stock Rises 13.3% (IART)
Comtex SmarTrend(R) - Tue Jan 27, 9:16AM CST
SmarTrend identified an Uptrend for Integra LifeSciences (NASDAQ:IART) on December 12th, 2014 at $50.30. In approximately 2 months, Integra LifeSciences has returned 13.31% as of today's recent price of $56.99.
IART: 56.89 (+0.62)
Integra LifeSciences Launches Integra(R) Reinforcement Matrix
GlobeNewswire - Wed Jan 21, 7:38AM CST
Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced the full market release of Integra(R) Reinforcement Matrix, a biological implant composed of porcine dermis that may be used for any type of tendon injury that requires surgical reconstruction. Tendon injuries are some of the most common musculoskeletal disorders, ranging from a mild ankle sprain to an Achilles tendon rupture or flexor tendon injury of the hand.
IART: 56.89 (+0.62)
Integra LifeSciences Announces Resolution of Warning Letter Related to Its Manufacturing Facility in Anasco, Puerto Rico
GlobeNewswire - Tue Jan 20, 7:00AM CST
Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced the United States Food and Drug Administration (the "FDA"
has informed the Company that it had addressed the violations in the warning letter relating to its manufacturing facility in Anasco, Puerto Rico (the "Anasco" facility). IART: 56.89 (+0.62)
Integra reports February 24
Seeking Alpha - at Seeking Alpha - Wed Jan 14, 3:18PM CST
IART: 56.89 (+0.62)
Integra LifeSciences to Host Its Fourth Quarter 2014 Earnings Results Conference Call on February 24, 2015
GlobeNewswire - Wed Jan 14, 3:05PM CST
Integra LifeSciences Holdings Corporation (Nasdaq:IART) will release its fourth quarter 2014 financial results and issue 2015 financial guidance on Tuesday, February 24, 2015. The company has scheduled a conference call for 8:30 AM ET the same day to discuss the results.
IART: 56.89 (+0.62)
Integra LifeSciences Acquires Metasurg's Foot and Ankle Product Portfolio
GlobeNewswire - Mon Jan 12, 8:16AM CST
Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced that, in December, it closed on the acquisition of the product portfolio from Metasurg.
IART: 56.89 (+0.62)
Insider Trading Alert - STAG, KLAC And IART Traded By Insiders
at The Street - Tue Jan 06, 9:15AM CST
Stocks with insider trader activity include STAG, KLAC and IART
STAG: 25.49 (-0.11), IART: 56.89 (+0.62), KLAC: 63.64 (-0.23)
Integra LifeSciences to Participate in the 33rd Annual J.P. Morgan Healthcare Conference in January
GlobeNewswire - Mon Jan 05, 3:39PM CST
Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced that it will present at the 33 Annual J.P. Morgan Healthcare Conference.
IART: 56.89 (+0.62), JPM: 59.67 (+0.10)
Integra Lifesciences Holdings (IART) Highlighted As Strong And Under The Radar Stock Of The Day
at The Street - Wed Dec 31, 8:47AM CST
Trade-Ideas LLC identified Integra Lifesciences Holdings (IART) as a strong and under the radar candidate
IART: 56.89 (+0.62)
Integra LifeSciences Hits 52-Week High on Portfolio Strength - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 24, 12:00PM CST
Over the last few months, Integra LifeSciences Holdings Corporation (IART) has launched back-to-back products which we believe will enhance the overall product portfolio and also usher in more profitability for the company.
ZMH: 119.33 (+1.18), JNJ: 99.62 (+1.18), IART: 56.89 (+0.62), SYK: 94.51 (+1.14)
How to Invest Money: This Secret Could Save You Thousands
Brian Stoffel, The Motley Fool - Motley Fool - Mon Dec 22, 8:00AM CST
The secret of how to invest money is so simple these kids could get it right. Photo: Flickr user Mike King. Here at The Motley Fool, we try to avoid giving blanket advice on investing, because there are as many paths to financial independence as...
BEBE: 3.90 (+0.01), BIIB: 391.66 (-0.45), PSUN: 2.95 (unch), RECN: 17.46 (-0.15), VALU: 15.10 (+0.09), GRMN: 55.93 (+0.02), QSII: 17.04 (+0.38), AMED: 28.62 (+0.16), UMPQ: 16.82 (+0.17), YHOO: 44.42 (+0.50), RCL: 75.56 (-1.19), IART: 56.89 (+0.62), ATLC: 2.91 (+0.10), AEO: 14.68 (-0.12), ARMH: 49.92 (-0.49), CEB: 79.35 (+0.93), GPS: 41.20 (-0.37)
Integra Lifesciences Up on Launch of Bilayer Skin Product - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Dec 19, 12:40PM CST
This latest single-use skin product of Integra (IART) is at present the only pre-meshed bilayer matrix that has been approved by the FDA to treat patients with third-degree burns and the subsequent scar contracture.
BIIB: 391.66 (-0.45), IART: 56.89 (+0.62), ANIP: 62.69 (-0.43), AFFX: 11.45 (+0.02)
Integra LifeSciences Launches Integra(R) Meshed Dermal Regeneration Template
GlobeNewswire - Wed Dec 17, 7:30AM CST
Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced the expansion of its skin and wound product line with the introduction of IntegraMeshed Dermal Regeneration Template. Integra Meshed Dermal Regeneration Template has received Pre-Market Approval (PMA) from the United States Food and Drug Administration (FDA), and expects to begin a full market release in the United States in January 2015. Integra's newest skin product will be featured at the John A. Boswick Burn and Wound Care Symposium, February 14-18, 2015.
IART: 56.89 (+0.62)
Strong And Under The Radar Today: Integra Lifesciences Holdings (IART)
at The Street - Tue Dec 16, 10:44AM CST
Trade-Ideas LLC identified Integra Lifesciences Holdings (IART) as a strong and under the radar candidate
IART: 56.89 (+0.62)
Italy Tissue Engineered - Skin Substitutes Market Outlook to 2020: Key players covered include Organogenesis, Smith & Nephew and Molnlycke Health Care
M2 - Wed Dec 10, 11:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/gzsh2g/italy_tissue) has announced the addition of the "Italy Tissue Engineered - Skin Substitutes Market Outlook to 2020" report to their offering. Our new report, "Italy Tissue Engineered - Skin Substitutes Market Outlook to 2020", provides key market data on the Italy Tissue Engineered - Skin Substitutes market. The report provides value, in millions of US dollars, volume (in units) and average prices (in US dollars) within market segments - Synthetic Skin Substitutes, Biosynthetic Skin Substitutes and Biologic Skin Substitutes (Allograft (Cellular and Acellular) and Xenograft Acellular). The report also provides company shares and distribution shares data for each of these market categories, and global corporate-level profiles of the key market participants, pipeline products, and news and deals related to the Tissue Engineered - Skin Substitutes market wherever available. The data in the report is derived from dynamic market forecast models. The publisher uses epidemiology and capital equipment-based models to estimate and forecast the market size. The objective is to provide information that represents the most up-to-date data of the industry possible. The epidemiology-based forecasting model makes use of epidemiology data gathered from research publications and primary interviews with physicians to establish the target patient population and treatment flow patterns for individual diseases and therapies. Using prevalence and incidence data and diagnosed and treated population, the epidemiology-based forecasting model arrives at the final numbers. Key Topics Covered: 1 List of Tables 2 Introduction 3 Tissue Engineered - Skin Substitutes Market, Italy 4 Overview of Key Companies in Italy, Tissue Engineered - Skin Substitutes Market 5 Appendix Companies Mentioned: - Organogenesis, Inc. - Molnlycke Health Care AB - Smith & Nephew Plc - BSN medical GmbH - Integra LifeSciences Holdings Corporation - Kinetic Concepts, Inc. - Covidien plc For more information visit http://www.researchandmarkets.com/research/gz...aly_tissue
SNN: 35.82 (-0.28), IART: 56.89 (+0.62)
Asia-Pacific Tissue Engineered - Skin Substitutes Market Outlook to 2020: Key players covered include Japan Tissue Engineering and Smith & Nephew
M2 - Tue Dec 09, 3:47AM CST
Research and Markets (http://www.researchandmarkets.com/research/ctmnfq/asiapacific) has announced the addition of the "Asia-Pacific Tissue Engineered - Skin Substitutes Market Outlook to 2020" report to their offering. Our new report, "Asia-Pacific Tissue Engineered - Skin Substitutes Market Outlook to 2020", provides key market data on the Asia-Pacific Tissue Engineered - Skin Substitutes market. The report provides value, in millions of US dollars, volume (in units) and average prices (in US dollars) within market segments - Synthetic Skin Substitutes, Biosynthetic Skin Substitutes and Biologic Skin Substitutes (Allograft (Cellular and Acellular) and Xenograft Acellular). The report also provides company shares and distribution shares data for each of these market categories, and global corporate-level profiles of the key market participants, pipeline products, and news and deals related to the Tissue Engineered - Skin Substitutes market wherever available. The data in the report is derived from dynamic market forecast models. The publisher uses epidemiology and capital equipment-based models to estimate and forecast the market size. The objective is to provide information that represents the most up-to-date data of the industry possible. Key Topics Covered: 1 List of Tables 2 Introduction 3 Tissue Engineered - Skin Substitutes Market, Asia-Pacific 4 Tissue Engineered - Skin Substitutes Market, Australia 5 Tissue Engineered - Skin Substitutes Market, China 6 Tissue Engineered - Skin Substitutes Market, India 7 Tissue Engineered - Skin Substitutes Market, Japan 8 Tissue Engineered - Skin Substitutes Market, South Korea 9 Overview of Key Companies in Asia-Pacific Tissue Engineered - Skin Substitutes Market 10 Appendix Companies Mentioned: - Japan Tissue Engineering Co., Ltd. - Smith & Nephew Plc - PolyNovo Biomaterials Pty Ltd - Molnlycke Health Care AB - National Tissue Engineering Research Center - L&C Bio - BSN medical GmbH - Covidien plc - Kinetic Concepts, Inc. - CG Bio Inc. - Integra LifeSciences Holdings Corporation - HansBiomed Co., Ltd - Cellumed Co. Ltd For more information visit http://www.researchandmarkets.com/research/ct...siapacific
SNN: 35.82 (-0.28), IART: 56.89 (+0.62)
